STOCK TITAN

Exscientia Plc - EXAI STOCK NEWS

Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.

Exscientia Plc (EXAI) is a pioneer in AI-driven drug discovery, transforming pharmaceutical research through automated small molecule design. This page serves as the definitive source for tracking the company's latest developments, offering investors and industry observers timely updates on its groundbreaking work.

Access comprehensive coverage of financial results, research milestones, and strategic partnerships that define Exscientia's progress. Our curated news collection includes press releases on clinical advancements, technology innovations, and regulatory developments essential for understanding the company's trajectory.

Key updates feature Exscientia's AI-optimized drug candidates, collaborations with leading pharmaceutical organizations, and insights into their automated discovery platform. The resource is particularly valuable for tracking how machine learning accelerates compound design while maintaining rigorous quality standards.

Bookmark this page for efficient monitoring of Exscientia's contributions to biopharmaceutical innovation. Return regularly to stay informed about how their AI-first approach continues to reshape drug development timelines and methodologies.

Rhea-AI Summary

Exscientia (Nasdaq: EXAI) released its Q1 2024 business update. The company reported positive early Phase 1 results for its BMS-partnered EXS4318 (PKC-theta inhibitor) program. Initial Phase I data for GTAEXS617 (CDK7 inhibitor) and EXS74539 (LSD1 inhibitor) are expected in 2H24. Exscientia's AI-driven automation lab aims to streamline drug design processes, targeting $40M in annual savings by 2025. The company plans to reduce headcount by 20-25% by year-end, expecting savings despite incurring $7.4M-$9.6M in severance costs. Financially, Q1 revenue was $6.7M, down from $7.3M YoY, while R&D expenses dropped to $29.8M from $42.2M. Exscientia projects its cash reserves will fund operations into 2027. The company will host a conference call on May 21 to discuss these updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.44%
Tags
-
Rhea-AI Summary

Exscientia (Nasdaq: EXAI) will announce its first quarter 2024 financial results on May 21, 2024, before U.S. market opening.

The company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to discuss business updates and review the financial outcomes.

Investors can access the webcast through the 'Investors and Media' section on Exscientia's website or dial in using provided phone numbers and conference ID.

A replay will be available for 90 days in the 'Events and Presentations' part of the site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences earnings
-
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) announces advancements in pipeline, collaborations, and financial results for Q4 and full year 2023. Key highlights include progress in clinical trials, collaborations with pharma giants, and financial data showing revenue decline but strong cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.5%
Tags
none
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) will announce financial results for Q4 and full year 2023 on March 21, 2024. A conference call and webcast will be held to discuss business updates and financial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences earnings
-
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) management to participate in investor conferences in March, including TD Cowen 44th Annual Health Care Conference, Barclays 26th Annual Global Healthcare Conference, and KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
conferences
-
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) has announced the initiation of the EXCYTE-2 study, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company’s deep learning, single-cell precision medicine platform and actual patient clinical response. The study aims to collect blood and bone marrow samples from first-line patients with AML, with an option to expand to second-line patients, representing areas of high unmet medical need with low survival rates. The study will also evaluate the activity of EXS74539 (‘539), Exscientia’s LSD1 inhibitor, in a large clinically annotated sample set, with the potential to support the ongoing development of ‘539, particularly in the selection of patients for future clinical trials. This study builds on other previously initiated precision medicine focused studies, including EXALT-1 and EXCYTE-1, and continues the company's focus on establishing AI-led ex vivo drug testing in human tissue samples as the most comprehensive strategy for preclinical testing of novel therapies, additive to mouse and other animal models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) founder and Chief Executive, Professor Andrew Hopkins, has been appointed Commander of the Order of the British Empire (CBE) for services to Science and Innovation by His Majesty King Charles III. This recognition follows multiple prestigious honours recently received by both Andrew and Exscientia, the AI-driven precision medicine company he leads. Exscientia has won the Prix Galien USA for Best Digital Health Solution in late 2022 and the Prix Galien UK in the same category in May 2023. Andrew was also elected for life to two of the UK’s national academies, the Royal Society and the Academy of Medical Sciences. Additionally, Exscientia was named to the inaugural Fortune 50 AI Innovators list in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) announces a new discovery stage programme with Sanofi, aiming to design a potential best-in-class molecule. Exscientia is eligible for up to $45 million in upfront and preclinical milestone payments, with additional development, regulatory, and sales-based milestone payments of over $300 million and tiered royalties on product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
-
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) received a $2.3 million grant from Open Philanthropy to research harnessing the host interferon response for treating and preventing pandemic influenza. The grant is part of the wider Pandemic Antiviral Discovery initiative, aiming to develop novel antiviral medicines for future pandemics. Exscientia plans to utilize the grant to explore small molecule therapeutics that can activate the interferon response to control influenza and COVID-19 infections. This aligns with the company's commitment to pandemic preparedness, supported by the Bill & Melinda Gates Foundation in 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
Rhea-AI Summary
Exscientia plc (EXAI) management to participate in fireside chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.56%
Tags
conferences
Exscientia Plc

Nasdaq:EXAI

EXAI Rankings

EXAI Stock Data

633.18M
95.77M
25.9%
20.81%
2.15%
Biotechnology
Healthcare
Link
United Kingdom
Oxford